The Nephron journals/Nephron journals · 2008 · 50 citations · 0 references
MedicineNephrologyPathologyRenal PathologyRenal PathophysiologyRenal PharmacotherapyGlomerular DiseasesGlomerular PathophysiologyNephrotic SyndromeRenal DiseaseRenal Function TestsRenal PharmacologyBlood Urea Nitrogen To Creatinine RatioFocal Segmental Glomerulosclerosis TherapyHyperlipidemia In Nephrotic SyndromeNephrotic Syndrome TreatmentRenal Dysfunction BiomarkersSerum Total Protein
The effect of d-alpha-tocopherol on the progression of renal dysfunction was investigated in rats injected with adriamycin (ADR), a model of progressive glomerulosclerosis associated with the nephrotic syndrome. Treatment with d-alpha-tocopherol was started 1 day before or 1 day after ADR injections (BE-TOC or AF-TOC rats). When compared to rats without d-alpha-tocopherol treatment (ADR-CON rats), the serum total cholesterol and triglyceride levels were significantly lower in the BE-TOC and AF-TOC groups. In week 16, the LDL cholesterol level and the atherogenic index were both significantly lower in BE-TOC and AF-TOC rats than in ADR-CON rats. The urinary protein, serum creatinine, blood urea nitrogen, malondialdehyde, and systolic blood pressure levels as well as the glomerulosclerosis score were high in ADR-CON rats, and reduced in BE-TOC or AF-TOC rats. There were no significant differences in body weight and serum albumin between the three groups in week 16. It is concluded that d-alpha-tocopherol can improve hyperlipidemia and ameliorate glomerulosclerosis in rats with ADR-induced progressive renal failure. Thus, d-alpha-tocopherol may have the potential for clinical application to treat focal glomerulosclerosis.